Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.61 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.61 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200946 | 0.90 | HTR6 (0.62) | HTR6QRFPRERAP1ERAP2ALPL | |
| SCHEMBL4211773 | 0.90 | HTR6 (0.64) | HTR6QRFPRCHRM2CHRM1CHRM3 | |
| SCHEMBL4203969 | 0.88 | HTR6 (0.65) | HTR6QRFPRERAP1ERAP2 | |
| SCHEMBL4199135 | 0.88 | HTR6 (0.63) | HTR6QRFPRCHRM2CHRM1CHRM3 | |
| SCHEMBL4206118 | 0.85 | HTR6 (0.61) | HTR6QRFPRCHRM2CHRM1CHRM3 | |
| SCHEMBL4213931 | 0.85 | HTR6 (0.56) | HTR6QRFPRCHRM2CHRM1CHRM3 | |
| SCHEMBL4205945 | 0.85 | HTR6 (0.65) | HTR6QRFPRCHRM2CHRM1CHRM3 | |
| SCHEMBL4215531 | 0.84 | HTR6 (0.59) | HTR6QRFPRCHRM2CHRM1CHRM3 | |
| SCHEMBL4210386 | 0.84 | HTR6 (0.55) | HTR6QRFPRCHRM2CHRM1CHRM3 | |
| SCHEMBL4207426 | 0.84 | HTR6 (0.65) | HTR6QRFPRCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | claimed |
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1888517-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006126939-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | HTR6, HTR1A, HTR1D | HTR6 1/4885QRFPR 81/4885ERAP1 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.